NCT03249740 is a Phase 1 clinical trial of GB-102 in Neovascular Age-Related Macular Degeneration, sponsored by Graybug Vision.

Who is sponsoring NCT03249740?

NCT03249740 is sponsored by Graybug Vision.

What drugs are being tested in NCT03249740?

Interventions in NCT03249740: GB-102, Aflibercept.

What condition does NCT03249740 study?

NCT03249740 studies Neovascular Age-Related Macular Degeneration.

Is NCT03249740 still recruiting?

NCT03249740 is currently completed. Last updated 20 December 2019.

Last reviewed 2019-12-20 · How we verify

NCT03249740

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

Completed Phase 1 Last updated 20 December 2019

What this trial tests

Phase 1 trial testing GB-102 in Neovascular Age-Related Macular Degeneration in 32 participants. Completed in 16 January 2019.

Timeline

29 August 2017

Primary endpoint
13 September 2018

16 January 2019

Quick facts

Lead sponsor	Graybug Vision
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	32
Start date	29 August 2017
Primary completion	13 September 2018
Estimated completion	16 January 2019
Sites	8 locations across United States

Drugs / interventions tested

GB-102 — full drug profile →
Aflibercept (AFLIBERCEPT) — full drug profile →

Conditions studied

Neovascular Age-Related Macular Degeneration — all drugs for Neovascular Age-Related Macular Degeneration →

Sponsor

Graybug Vision — full company profile →

Who can join

50 and older, any sex, with Neovascular Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of single and repeated intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular degeneration.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Retinal vascular occlusions.
Scott IU, Campochiaro PA, Newman NJ, Biousse V. · · 2020 · cited 185× · PMID 33308475 · DOI 10.1016/s0140-6736(20)31559-2
Nanocarriers for ocular drug delivery: current status and translational opportunity.
Gorantla S, Rapalli VK, Waghule T, Singh PP, et al · · 2020 · cited 162× · PMID 35516960 · DOI 10.1039/d0ra04971a
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives.
Kim HM, Woo SJ. · · 2021 · cited 117× · PMID 33467779 · DOI 10.3390/pharmaceutics13010108
Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Qiu F, Meng T, Chen Q, Zhou K, et al · · 2019 · cited 82× · PMID 30912953 · DOI 10.1021/acs.molpharmaceut.8b01319
Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis.
Xu M, Fan R, Fan X, Shao Y, et al · · 2022 · cited 70× · PMID 36172053 · DOI 10.2147/dddt.s383101
Recent Advances in Age-Related Macular Degeneration Therapies.
Fabre M, Mateo L, Lamaa D, Baillif S, et al · · 2022 · cited 68× · PMID 36014339 · DOI 10.3390/molecules27165089
Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration.
ElSheikh RH, Chauhan MZ, Sallam AB. · · 2022 · cited 64× · PMID 36358978 · DOI 10.3390/biom12111629
Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020.
Samanta A, Aziz AA, Jhingan M, Singh SR, et al · · 2020 · cited 52× · PMID 32511123 · DOI 10.1097/apo.0000000000000291

Verify or expand the search:

Other trials of GB-102

Trials testing the same drug.

NCT04085341 — A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion · Phase 2 · completed

Other recruiting trials for Neovascular Age-Related Macular Degeneration

Currently open trials in the same condition.

NCT06491914 — A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related · Phase 3 · active not recruiting
NCT06223958 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects Wi · Phase 3 · active not recruiting
NCT03683251 — Extension Study for the Port Delivery System With Ranibizumab (Portal) · Phase 3 · recruiting

Other Graybug Vision trials

Trials by the same sponsor.

NCT03953079 — A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD · Phase 2 · completed
NCT04085341 — A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03249740 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Graybug Vision
Last refreshed: 20 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03249740.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing